Table 1.
Demographic and clinical characteristics by UCLA GIT total score*
| Characteristics | All patients (N = 907) | None‐to‐mild score (n = 445) | Moderate (n = 231) | Severe to very severe score (n = 177) | P |
|---|---|---|---|---|---|
| Female, n (%) | 733 (86.2) | 365 (82.6) | 203 (87.9) | 165 (93.2) | 0.002 |
| Disease duration, mean (SD), y | 14.2 (7.7–22.5) | 12.75 (6.1–20.4) | 14.2 (8.5–22.9) | 16.8 (11.6–26.5) | <0.001 |
| Disease subtype, n (%) | |||||
| Limited | 611 (76.9) | 316 (78.6) | 171 (77.0) | 124 (72.5) | – |
| Diffuse | 184 (23.1) | 86 (21.4) | 51 (23.0) | 47 (27.5) | 0.29 |
| Death (all‐cause mortality), n (%) | 53 (5.8) | 27 (6.1) | 15 (6.5) | 11 (6.3) | 0.98 |
| ANA centromere (+), n (%) | 361 (44.73) | 163 (39.5) | 105 (47.7) | 93 (53.4) | 0.005 |
| Scl‐70 (+), n (%) | 134 (14.8) | 78 (18.9) | 33 (15.4) | 23 (13.6) | 0.24 |
| U1 RNP (+), n (%) | 56 (6.1) | 36 (8.8) | 10 (4.7) | 10 (5.9) | 0.14 |
| Digital ulcers, n (%) a | 415 (45.8) | 187 (42.0) | 111 (48.1) | 117 (66.1) | <0.001 |
| Calcinosis, n (%) a | 147 (16.2) | 65 (14.9) | 37 (16.3) | 45 (25.7) | 0.006 |
| Myositis, n (%) a | 30 (3.3) | 19 (4.3) | 8 (3.5) | 3 (1.7) | 0.29 |
| Myocardial disease, n (%) a | 9 (0.9) | 2 (0.4) | 4 (1.7) | 3 (1.7) | 0.20 |
| PAH, n (%) b | 62 (7.3) | 27 (6.1) | 21 (9.1) | 14 (7.9) | 0.33 |
| ILD, n (%) c | 267 (34.5) | 139 (34.5) | 65 (30.7) | 63 (39.4) | 0.22 |
| PPI use, n (%) a | 702 (82.39) | 324 (73.0) | 207 (89.6) | 171 (96.6) | <0.001 |
| Employed, n (%) | 342 (37.7) | 207 (46.5) | 91 (74.6) | 44 (51.2) | <0.001 |
| Pseudo‐obstruction, n (%) | 29 (3.5) | 5 (1.1) | 6 (2.6) | 18 (10.2) | <0.001 |
| Malabsorption, n (%) | 26 (3.3) | 3 (0.7) | 7 (3.3) | 16 (9.5) | <0.001 |
The categorical variables are compared with a P value, which was calculated using the chi‐square test for categorical variables and using the Kruskal‐Wallis equality‐of‐populations rank test for continuous variables. ANA, antinuclear antibody; ILD, interstitial lung disease; PAH, pulmonary arterial hypertension; PPI, proton pump inhibitor; SD, standard deviation; UCLA GIT, University of California, Los Angeles, Scleroderma Clinical Trials Gastrointestinal Tract 2.0 Questionnaire.
Ever recorded during follow‐up.
PAH was defined as mean PAP >20 mm Hg, a pulmonary capillary wedge pressure ≤15 mm Hg, and pulmonary vascular resistance >2 Woods units on right‐sided heart catheterization.
ILD was defined as the presence of characteristic pulmonary fibrosis on high‐resolution computed tomography of the chest.